- Home
- ECAT vs PGEN Comparison
ECAT vs PGEN Comparison
Compare ECAT & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ECAT | PGEN |
|---|---|---|
| Founded | 2021 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.6B |
| IPO Year | 2021 | 2013 |
Fundamental Metrics
Financial Performance| Metric | ECAT | PGEN |
|---|---|---|
| Price | $15.83 | $7.06 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $8.33 |
| AVG Volume (30 Days) | 507.8K | ★ 4.8M |
| Earning Date | 01-01-0001 | 05-13-2026 |
| Dividend Yield | ★ 9.20% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.03 |
| Revenue | N/A | ★ $230,981,000.00 |
| Revenue This Year | N/A | $1,115.92 |
| Revenue Next Year | N/A | $81.04 |
| P/E Ratio | ★ $6.32 | $235.50 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.36 | $1.80 |
| 52 Week High | $17.14 | $7.32 |
Technical Indicators
Market Signals| Indicator | ECAT | PGEN |
|---|---|---|
| Relative Strength Index (RSI) | 63.30 | 72.86 |
| Support Level | $14.93 | $3.37 |
| Resistance Level | $16.09 | N/A |
| Average True Range (ATR) | 0.18 | 0.41 |
| MACD | 0.07 | 0.14 |
| Stochastic Oscillator | 97.08 | 87.41 |
Price Performance
Historical ComparisonAbout ECAT BlackRock ESG Capital Allocation Term Trust of Beneficial Interest
BlackRock ESG Capital Allocation Trust is a non-diversified, closed-ended management investment company. The Trust's investment objectives are to provide total return and income through a combination of current income, current gains, and long-term capital appreciation.
About PGEN Precigen Inc.
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.